CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...